ReveraGen, Actelion deal

Actelion and ReveraGen partnered to develop and commercialize vamorolone to treat Duchenne muscular dystrophy (DMD). Actelion has already paid $10 million in R&D expenses and will also provide up to $1 million per year for the next three years for R&D. Actelion gained an option for exclusive, worldwide rights that it may exercise at two stages of development but no later than prior to data from a planned Phase IIb trial. ...